Stocks Health care ARGX
NASDAQ · Health careArgenx SE (ARGX)
Operating cash flow minus capital spending left $679M of free cash flow in fiscal 2025. At December 31, 2025 it held $3.5B in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 19, 2026.
Key facts about Argenx SE
- Net worth
- Argenx SE has a market value (market cap) of $59.7B at the latest share price, and shareholders' equity of $7.3B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $35.5M (+254.4% year on year), with a net loss of $295.1M.
- Cash flow
- In fiscal 2025 operations brought in $685.2M of cash; after $6.2M of capital spending, free cash flow was $679M.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 19, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Argenx SE does
argenx is a biotechnology company that develops antibody-based medications for autoimmune diseases and cancer. Its primary commercial product, efgartigimod, treats generalized myasthenia gravis, a condition causing severe muscle weakness. The company sells its prescription therapies directly to healthcare providers, hospitals, and pharmacies globally. Its shares trade on NASDAQ under the ticker ARGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | $1.3B | $19.57 | $679M |
| 2024 | n/a | $833M | $12.78 | -$84.5M |
| 2023 | $35.5M | -$295.1M | -$5.16 | -$421.1M |
| 2022 | $10M | -$709.6M | -$13.05 | -$863.6M |
| 2021 | $497.3M | -$408.3M | -$7.99 | -$610.4M |
| 2021 | $41.2M | -$608.5M | -$13.40 | -$399.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Argenx SE has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- October 22, 2026
- October 19, 2026
- October 8, 2026
- September 29, 2026
- August 27, 2026
- August 27, 2026Tender offer (amended) SC TO-T/A
- August 19, 2026Tender offer (amended) SC TO-T/A
Insider trades
What the people running Argenx SE did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns ARGX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 8.7% | May 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 506 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 5,231,452 | +240,418 |
| Jupiter Topco LLC | 2,474,015 | new |
| Capital World Investors | 2,199,770 | -56,446 |
| Artisan Partners Limited Partnership | 1,508,778 | +40,796 |
| Avoro Capital Advisors LLC | 1,000,000 | 0 |
| Wellington Management Group Llp | 930,548 | -90,909 |
| BlackRock, Inc. | 777,237 | -31,100 |
| Rtw Investments, LP | 709,446 | 0 |
| Morgan Stanley | 643,123 | +82,412 |
| Invesco Ltd. | 443,990 | -150,707 |
| Bank of America Corp | 400,234 | +117 |
| Alliancebernstein L.P. | 395,661 | -26,643 |
| Bellevue Group AG | 301,000 | -12,000 |
| Sands Capital Management, LLC | 298,599 | -41,686 |
| William Blair Investment Management, LLC | 264,617 | -1,450 |
| Sei Investments Co | 255,073 | -31,893 |
| Clearbridge Investments, LLC | 253,776 | +22,420 |
| Jennison Associates LLC | 226,200 | -11,268 |
| Franklin Resources Inc | 224,930 | -8,563 |
| Citadel Advisors LLC | 212,416 | -6,710 |
Insiders
Questions about ARGX
What does Argenx SE do?
argenx is a biotechnology company that develops antibody-based medications for autoimmune diseases and cancer. Its primary commercial product, efgartigimod, treats generalized myasthenia gravis, a condition causing severe muscle weakness. The company sells its prescription therapies directly to healthcare providers, hospitals, and pharmacies globally. Its shares trade on NASDAQ under the ticker ARGX.
What is Argenx SE's net worth?
Argenx SE has a market value (market cap) of $59.7B at the latest share price, and shareholders' equity of $7.3B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Argenx SE profitable?
Yes. In fiscal 2025 it reported net income of $1.3B.
When did Argenx SE last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 19, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 9, 2026.
Similar companies
Compare ARGX with
Follow ARGX
Get an email when Argenx SE files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Argenx SE tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.